Results 11 to 20 of about 23,244 (239)

Cuproptosis in ccRCC: key player in therapeutic and prognostic targets [PDF]

Frontiers in Oncology, 2023
BackgroundClassical biomarkers have been used to classify clear cell renal cell carcinoma (ccRCC) patients in a variety of ways, and emerging evidences have indicated that cuproptosis is closely related to mitochondrial metabolism, thereby accelerating the development and progression of ccRCC. Nevertheless, the specific relationship between cuproptosis
Yang Lv, Qiang Li, Lu Yin, Shaohua He, Chao Qin, Zhongwen Lu, Hongqi Chen   +6 more
openaire   +4 more sources

A multiomics disease progression signature of low-risk ccRCC [PDF]

Scientific Reports, 2022
AbstractClear cell renal cell carcinoma (ccRCC) is the most common renal cancer. Identification of ccRCC likely to progress, despite an apparent low risk at the time of surgery, represents a key clinical issue. From a cohort of adult ccRCC patients (n = 443), we selected low-risk tumors progressing within a 5-years average follow-up (progressors: P, n =
Strauss, Philipp, Rivedal, Mariell, Scherer, Andreas, Eikrem, Øystein Solberg, Nakken, Sigrid, Beisland, Christian, Bostad, Leif, Flatberg, Arnar, Skandalou, Eleni, Beisvag, Vidar, Furriol, Jessica, Marti, Hans Peter   +11 more
openaire   +7 more sources

Triggering SORL1 Expression Restricts ccRCC Progression by Inducing Ubiquitination-Mediated c-Myc Degradation. [PDF]

Cancer Sci
Targeted triggering of SORL1 expression through a novel MPOC delivery system could inhibit ccRCC progression through binding to TRIM22 and further promoting ubiquitination‐mediated C‐MYC degradation, thereby facilitating the inhibition of oxidative phosphorylation through transcriptional repression of ACO2 and IDH2.
Wang K, Song W, Bai Q, Shen S, Lu X, Su C, Yang S, Wang Y, Xia Y, Zan R, Jiang S, Guo J.   +11 more
europepmc   +2 more sources

Knockdown of RPL28 Inhibits the Progression of Clear Cell Renal Cell Carcinoma. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive histological subtype of kidney cancer. Previous studies have implicated ribosomal protein L28 (RPL28) in the progression of various cancers; however, its role in ccRCC remains unclear.
Luo R, Wu G, Xie Z, Xiao Y, Zhu W, Jiang H.   +5 more
europepmc   +2 more sources

Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Clear cell renal cell carcinoma (ccRCC) is hallmarked by profound metabolic reprogramming; however, its intricate crosstalk with the tumor immune microenvironment (TIME) and its clinical ramifications remain inadequately elucidated.
Peng Y, Qin S, Li X, Wan L, Guan R.
europepmc   +2 more sources

ccRCC proteome quantification matrix

, 2021
ccRCC proteome quantification ...
Jinwen Feng (11829878)
core   +1 more source

Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery [PDF]

, 2014
Background:Wider clinical applications of 9p status in clear cell renal cell carcinoma (ccRCC) are limited owing to the lack of validation and consensus for interphase fluorescent in situ hybridisation (I-FISH) scoring technique.
Fleming, S., P Rauchhaus, J Fitzpatrick, Fitzpatrick, J., N Pratt, S Fleming, J Bondad, J Cunningham, El-Mokadem, I., Cunningham, J., Bondad, J., Nabi, G., Rauchhaus, P., G Nabi, Pratt, N., I El-Mokadem   +15 more
core   +1 more source

Dietary Polyphenol Acteoside-Related Molecular Signatures in Clear Cell Renal Cell Carcinoma: Multi-Omics Profiling and Functional Validation of IMPDH1. [PDF]

Food Sci Nutr
Acteoside‐related molecular signatures were integrated with bulk, single‐cell, and spatial transcriptomic data to characterize clear cell renal cell carcinoma (ccRCC) heterogeneity. Two molecular subtypes (C1 and C2) showed distinct clinical, metabolic, immune, and genomic features.
Chen X, Zhang D, Ji Z, Sun S, Wang J, Shen S, Zhu J.   +6 more
europepmc   +2 more sources

Variation in the gene encoding the co-inhibitory molecule BTLA is associated with survival in patients treated for clear cell renal carcinoma – results of a prospective cohort study

Archives of Medical Science, 2021
Introduction The successful introduction of immune checkpoint blockade approaches to renal-cell carcinoma (RCC) treatment indicates the importance of molecules regulating the T cell response to RCC risk and progression.
Krzysztof Tupikowski, Anna Partyka, Edyta A. Pawlak, Kuba Ptaszkowski, Romuald Zdrojowy, Irena Frydecka, Agnieszka Hałoń, Lidia Karabon   +7 more
doaj   +1 more source

UDP-Glucose-6-Dehydrogenase Mediated O-GlcNAcylation of Tight Junction Protein 1 Suppresses Metastasis in Renal Cell Carcinoma. [PDF]

Adv Sci (Weinh)
Our research unveiled a regulatory paradigm wherein TRIM25 orchestrates the ubiquitin‐mediated degradation of UGDH. UGDH modulates the protein stability of TJP1 by regulating O‐GlcNAcylation levels, effectively impeding the metastasis of ccRCC. Our insights elevate UGDH to a pivotal biomarker and tumor suppressor, marking the first demonstration that ...
Chen X, Bao Y, Liu T, Qiu J, Ma Y, Zhang Z, Wang C, Deng R, Song Z, He T, Liu H, Zhou J, Wang Y, Gong K.   +13 more
europepmc   +2 more sources